PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/AYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts will review the presentation and diagnosis of AD and discuss the current evidence and guidelines for treatment selection for pediatric and adult patients. The faculty will also offer their thoughts on engaging with patients to provide personalized care and improved outcomes. Learn from the data and the experts in this informative, engaging discussion. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD), Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines, Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care.

Go online to PeerView.com/XZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent validation of novel multitargeted TKIs and immune checkpoint inhibitor therapies in metastatic disease, the treatment horizon of renal cell carcinoma (RCC) has vastly expanded and has continued to broaden with the emergence of long-term data supporting the efficacy of dual checkpoint blockade and combination therapies involving immunotherapy/TKI partners. Despite recent regulatory approvals, guideline updates, and abundant evidence, many medical and urologic oncologists find it challenging to bring these novel immune and targeted strategies into clinical practice. Designed to bridge the gap between theory and practice, this educational activity features expert guidance on how oncologists and urologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Featuring cases drawn from practice, participants will hear how peers resolve clinical issues as the faculty present best practices for individualized RCC treatment. Upon completion of this CE activity, participants will be able to: Choose appropriate, personalized treatment regimens that make use of recent clinical research findings on validated immune and targeted therapies for patients across the disease spectrum, including resectable disease, newly diagnosed metastatic, or previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for patients with RCC in different disease and treatment settings, Incorporate practical strategies to mitigate and manage AEs related to targeted and immune-based therapies for patients with RCC.

Go online to PeerView.com/ZWH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite a widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, there has been unequal progress with increasing access to treatment and reducing the number of new HIV infections and AIDS-related deaths, resulting in several vulnerable populations being left behind. Stigma and discrimination, together with other social inequalities and exclusion, are proving to be key barriers in battling this epidemic. In this activity, based on a recent live web broadcast, provider and patient perspectives on overcoming barriers to modern HIV treatment strategies will be examined. Additionally, the engaging panel will discuss the importance of establishing strong patient–provider relationships and demonstrating an understanding of the unique challenges faced by each individual patient living with HIV. Upon completion of this CE activity, participants should be better able to: Apply updated evidence-based guidelines and recent clinical data when recommending initial antiretroviral therapy (ART) regimens and switch strategies for individual patients infected with HIV, Assess the potential impact of clinical trial data related to emerging therapeutic strategies for HIV, Effectively prevent or manage drug–drug interactions, adverse events, and other complications associated with HIV, ART, and comorbidities, Establish strong patient–provider relationships, and demonstrate an understanding of the unique challenges faced by each individual patient living with HIV, Develop strategies within the healthcare team to link people living with HIV to essential HIV care, treatment, and support services.

Go online to PeerView.com/ZQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Seminar & Multidisciplinary Tumor Board program will pair insightful commentary on emerging systemic and locoregional options in HCC with clinical insights from different disciplines. Each Tumor Board segment will feature a case-centered discussion on the increasingly important multidisciplinary team-based management of patients across the HCC disease continuum. Hear an in-depth conversation on how the HCC management team can successfully collaborate to offer the best possible care to their patients. Upon completion of this CE activity, participants will be better able to: Assess the latest efficacy and safety evidence on available and emerging systemic treatments, including multikinase inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors (as monotherapy or within a combination strategy) for patients with advanced HCC, Review ongoing clinical trials and recent data for innovative strategies, including tumor treating fields, and locoregional combinations with systemic therapies, across the HCC disease spectrum, Develop personalized treatment plans for patients with early- to advanced-stage HCC, inclusive of clinical trial enrollment when appropriate, that are based on the latest clinical evidence, practice guidelines, treatment history, and other patient- and disease-specific factors, Apply best practices for collaboration and coordination of care among the multidisciplinary HCC care team to optimize patient assessment and treatment and minimize treatment-related toxicities.

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Go online to PeerView.com/FFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Sjögren’s Syndrome reviews current concepts in the pathophysiology of pSS, and discusses the obstacles faced in recent clinical trials and how new approaches may overcome these obstacles in the future. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with primary Sjögren’s Syndrome, Describe key pathways involved in the pathology of primary Sjögren’s Syndrome and implications for treatment, Evaluate recent clinical trial data related to emerging treatment options for primary Sjögren’s Syndrome, Identify patients who might derive benefit from novel therapeutic options for primary Sjögren’s Syndrome.

Go online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestations. These experts provide practical guidance on strategies and techniques for diagnosing, staging, and managing patients who present with various cardiac irAEs. This virtual session will engage participants with opportunities to participate in consultative assessments of real-world patient cases, including contributing to key aspects of diagnostic decision-making and deliberation of optimal strategies for collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Summarize the prevalence, biologic mechanisms, burden, and consequences of the development of cardiac immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Utilize algorithms and practical tools based on the latest clinical evidence and recommendations for identification, diagnosis/differential diagnosis, treatment, and management of cardiac irAEs, Integrate shared decision-making, team-based approaches, and telemedicine to facilitate multidisciplinary and interprofessional collaboration and care coordination and improve clinician-patient communication and patient outcomes.

Go online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Orally bioavailable CDK4 and 6 inhibitors have become established standard-of-care options in HR+/HER2- metastatic breast cancer, and these agents are now expected to have a major impact in early breast cancer (EBC). CDK4 and 6 inhibition has recently shown significant benefit as adjuvant therapy in patients at high risk of early recurrence, but other studies in the adjuvant and neoadjuvant settings are under way as well. How should these advances be transitioned to the clinic based on the accumulating supportive evidence? How can surgeons and oncologists work together to ensure proper risk assessment and treatment planning to improve outcomes in patients with HR+/HER2- EBC? This PeerView Virtual Workshop provides pertinent updates on the most recent research and available evidence on CDK4 and 6 inhibition in HR+/HER2- EBC, as well as practical, case-based guidance on the application of these agents using individualized treatment plans and effective multidisciplinary collaboration. Upon completion of this CE activity, participants will be able to: Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence, Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 & 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease, Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatment plans in order to optimize health outcomes and promote long-term weight loss. Upon completion of this CE activity, participants will be able to: Recognize the role of weight-loss pharmacotherapy used adjunct to other treatment approaches for addressing obesity pathophysiology, including metabolic adaptation, Assess available evidence on current and emerging GLP-1–based weight-loss pharmacotherapies, including long-term efficacy and safety data, Incorporate GLP-1–based weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Go online to PeerView.com/AMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance. Upon completion of this CE activity, participants will be able to: Summarize the mechanistic and selectivity differences among covalent and noncovalent BTK inhibitors, including their implications for off-target effects, agent safety profiles, and therapeutic intolerance, Describe the mechanisms of BTK inhibitor resistance, including core mechanisms of acquired resistance to covalent agents and how noncovalent inhibitors can overcome resistance mutations.